VANCOUVER, British Columbia & SEATTLE, June 10, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that its board of directors (the "Board") has adopted a limited-duration shareholder rights plan (the "Rights Plan"). The Board adopted the Rights Plan in response to the unsolicited, non-binding proposal by All Blue Falcons FZE ("All Blue") to acquire Zymeworks and All Blue’s continued share accu
VANCOUVER, British Columbia & SEATTLE, May 27, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:
VANCOUVER, British Columbia & SEATTLE, May 26, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced new clinical data for the HER2‑targeted bispecific antibody zanidatamab in both HER2-positive breast cancer and gastric/gastroesophageal junction adenocarcinoma. The data are being presented in two separate poster sessions at the American Society of Clinical Oncology (ASCO) Annual Meeting June 3-7,